🇺🇸 FDA
Pipeline program

CYP2C19 genotyping

PGxSTEMI08

Approved gene_therapy completed

Quick answer

CYP2C19 genotyping for Myocardial Infarction is a Approved program (gene_therapy) at Vera Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Vera Therapeutics
Indication
Myocardial Infarction
Phase
Approved
Modality
gene_therapy
Status
completed

Clinical trials